3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hematologic Diseases
1
Granulosa Cell Tumor
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Interventions
Carboplatin
4
Sunitinib
3
Rituximab
3
Pemetrexed
3
ponatinib
2
pembrolizumab
2
osimertinib
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
ricolinostat
1
pralsetinib
1
pomalidomide
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
emvododstat
1
atezolizumab
1
Temozolomide
1
Taxes
1
Sorafenib
1
Papanicolaou Test
1
Paclitaxel
1
Melphalan
1
Irinotecan
1
Interleukin-2
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Histologic Type
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts